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Abstract  1 
Many questions about the long-term effects of combination antiretroviral therapy (cART) on clinical 2 
outcomes in people living with HIV (PLWH) and their impact on health systems remain unanswered. The 3 
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) was formed in 2005 to 4 
pool and harmonize existing longitudinal data on people living with HIV in Europe, to answer key 5 
research questions that could not be addressed adequately by individual cohorts.  Key research 6 
questions include long-term prognosis, rare outcomes, and variations across patient groups, settings 7 
and health systems. COHERE uses the HIV Cohorts Data Exchange Protocol, a standardized and validated 8 
method of data structure and transfer, to compile data from over 40 cohorts of PLWH residing in 9 
Europe, representing 331 481 individuals, including 2808 children (<13), representing 2 135 896 person-10 
years of follow-up. COHERE compiles data on clinical characteristics, antiretroviral therapy and other 11 
medications, HIV seroconversion, opportunistic infections, laboratory results and socio demographic 12 
data. External collaborators interested in conducting a project in COHERE should submit a project 13 
proposal to the Regional Coordinating Centres in Bordeaux and Copenhagen for review by COHERE’s 14 
governing bodies (see www.cohere.org for further information). 15 
 16 
Key Messages:  17 
 COHERE adds value by focusing on questions that cannot be addressed by single cohorts 18 
because of sample size requirements, ensuring the sustainability of individual cohorts. 19 
 Recent and exemplary reports by COHERE suggest that earlier and more widespread testing for 20 
HIV with linkage to care was required to reduce the incidence of late presentation. 21 
 Non-injection drug users living with HIV with CD4 cell counts above 500/mm3 after starting cART 22 
had mortality patterns similar to those in the general population.  23 
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 COHERE has informed models of HIV progression and the effect of therapy which have been 1 
used to characterize HIV-infected populations, inform public health policy and serve as a basis 2 
for cost-effectiveness analysis. 3 
  4 
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Why was COHERE set up?  1 
Widespread access to effective combination antiretroviral therapy (cART), beginning in 1996, 2 
dramatically reduced the number of AIDS-related events and deaths in people living with HIV (PLWH) in 3 
high-income settings.(1) The study of prognosis and specific clinical outcomes therefore requires larger 4 
populations. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) was 5 
founded in 2005 to continue to advance epidemiological research on the prognosis of PLWH in Europe. 6 
COHERE has expanded and strengthened collaborative efforts in Europe and facilitated those with other 7 
regions by ensuring that longitudinal data, the product of early investments in clinic-based databases 8 
and observational studies, were compiled and harmonized. In 2011, COHERE joined three other 9 
European HIV collaborations, PENTA, EuroSIDA, and CASCADE to form “EuroCoord”, a Network of 10 
Excellence funded by the European Commission Seventh Framework Programme.(2) COHERE also 11 
collaborates with the ART Cohort Collaboration (ART-CC) and the International Epidemiologic Databases 12 
to Evaluate AIDS (IeDEA) global network.(3, 4) 13 
How does COHERE operate?  14 
COHERE operates according to the principles set out in Box 1. Projects in COHERE provide added value 15 
by only addressing scientific questions that cannot be answered by participating cohorts.  16 
Two Regional Coordinating Centres (RCCs), based at the University of Bordeaux’s Institut de Santé 17 
Publique, d'Épidémiologie et de Développement (ISPED) in Bordeaux, France and the Center for Health 18 
and Infectious Diseases Research (CHIP), Department of Infectious Diseases and Rheumatology, 19 
Rigshospitalet, in Copenhagen, Denmark, maintain COHERE’s infrastructure. The COHERE Steering 20 
Committee (SC) -- composed of representatives from the participating cohorts -- oversees the COHERE 21 
Collaboration, ensuring compliance with its principles; it also elects the Chair and the “Regional 22 
Representatives” to the COHERE Executive Committee (EC). The EC -- composed of three 23 
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representatives from each of the two regions, and the two RCC Heads -- acts as the functional link 1 
between the RCCs and the SC.  2 
COHERE projects are organized by “themes” (Prognosis and the effect of antiretroviral therapy (ART), 3 
Hepatitis, Opportunistic Infections, Malignancies, Late Presentation, and Socio-economic Inequalities) 4 
to encourage collaboration and streamline the project proposal process. Theme Leads stimulate 5 
scientific enquiry within their theme and develop projects. A detailed account of how COHERE operates 6 
is described in the Manual of Operations (www.cohere.org).   7 
Who participates in COHERE? 8 
COHERE has grown from 33 cohorts in 2005 to 40 in 2015. COHERE initially approached cohorts because 9 
of their proven ability to address scientific questions and collect good quality data at clinical sites. As 10 
COHERE is a project-based collaboration, the data pooled in annual mergers depend on the projects 11 
included. Western European countries with longstanding national cohorts contribute a large proportion 12 
of person-years of follow-up, but there is  an increasing number of individuals in care in Eastern Europe, 13 
primarily via the EuroSIDA network.(5) Figure 1 presents the number of people living with HIV (excluding 14 
deaths) included in COHERE as of 31/12/2011 as a percentage of UNAIDS 2011 estimates of people 15 
living with HIV by country.  16 
COHERE includes both clinic/hospital-based cohorts of HIV-infected individuals, where data are 17 
extracted primarily from medical records in the context of routine care, and interval cohorts of specific 18 
populations of HIV-infected people, where data are collected at regular intervals that are unrelated to 19 
participants ongoing health care. Since people with HIV are seen regularly over a long period of time at 20 
a clinic/hospital, and are not just attending at times when they are symptomatic, the group of people 21 
seen at a given hospital naturally forms a cohort. Table 1a and 1b present a complete list of the cohorts, 22 
their characteristics and funding sources. All COHERE cohorts follow local ethical standards.  23 
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The 2014 merger included data from 331 481, including 2,808 children (<13), representing 2 135 896 1 
person-years of follow-up. Table 2a highlights the demographic characteristics and prognostic markers 2 
of HIV in those aged 13 and older enrolled in adult cohorts. Approximately a quarter of the COHERE 3 
sample is female (27%). The median age at inclusion is 35 [IQR: 30, 43]. The primary mode of HIV 4 
transmission is sexual contact [homosexual/bisexual contact (38.7%), heterosexual contact (37%)], 5 
followed by injection drug use (IDU) (13.5%). Overall, 71.6% of the sample has never had a clinical AIDS 6 
diagnosis before or during enrolment. The median CD4 cell count at enrolment, defined as the period 7 
six months prior to and one month after enrolment date, was 340 cells/mm3 [IQR: 170, 530] in adults 8 
(Table 2a).  Of those with an available CD4 cell counts at enrolment, 29% had <200 cells/mm3, 22% had 9 
between 200 and 350 cells/mm3, and 49% had >350 cells/mm3. Of those younger than age 13 (N=2808, 10 
representing 23 458), 93.7% were infected via vertical transmission and 73.4% had never had an AIDS 11 
diagnosis (Table 2b).  12 
How often have they been followed up?  13 
As a consortium of cohorts comprising clinic and interval cohorts, patient follow-up varies. For clinic or 14 
hospital-based cohorts, average patient follow-up reflects current standards of care in those countries.  15 
A derived measure of lost to follow-up (LTFU) was constructed by estimating the median last clinical 16 
encounter (defined as either visit and/or the date of last laboratory test) per active cohort. Those 17 
individuals who had not had a clinical encounter in the 18-months prior to this date were considered to 18 
be LTFU.  Those who died during the same period were excluded.  On average, 25% of the COHERE 2014 19 
sample met this definition of LTFU, with variation between cohorts.  LTFU in paediatric cohorts was 20 
estimated among those under age 17 as many cohorts discontinue follow-up at age 18.  LTFU among 21 
paediatric patients aged <17 (N = 1,960) was 20% overall and ranged from 1.8-22% across cohorts. 22 
  23 
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What data are collected and how?  1 
COHERE has benefited from dynamic data management processes, which have evolved to 2 
accommodate new projects and scientific questions. COHERE’s Data Managers (DMs) work with Project 3 
Leads and Statisticians to conduct preliminary surveys, feasibility studies and, occasionally, collect 4 
additional data. COHERE collects data on basic clinical information including: date of first HIV positive 5 
test, estimated date of seroconversion, cART and other medications, opportunistic infections, and 6 
laboratory results (CD4, CD8, plasma viral load values, hepatitis B and C serological tests, and HIV drug 7 
resistance tests), as well as socio-demographic data (see www.hicdep.org for more information about 8 
the definition of different variables). COHERE, via EuroCoord, conducts an inventory of data items and 9 
biological samples collected by participating cohorts. The submission of data to COHERE is facilitated by 10 
the use of the HIV Cohorts Data Exchange Protocol (HICDEP), a flexible data structure, developed in 11 
2004, to guide the mapping of individual cohort data into a standard format to facilitate data merging.(6)   12 
For approved projects, COHERE DMs organize data collection by developing a standardized operating 13 
procedure (SOP) for individual cohort DMs. Each cohort retains the right to “opt out” of any or all of the 14 
projects in a given merger. Data are submitted via the HIV-Distributed Data Management Tool (7)  and 15 
must pass all format and edit checks, defined in HICDEP, before they can be submitted. Cohorts are 16 
given an 8-week window to address data inconsistencies before the final submission. Once data are 17 
merged, likely duplicate patient records between and within cohorts are identified using probability 18 
linkage. Data items used are gender, year of birth, treatment history, viral load measurements and CD4 19 
cell counts. Duplicate records are reconciled based on prior agreements between participating cohorts. 20 
DMs identified and resolved 20,953 duplicate records in 2014. Cohorts resolve issues identified over 21 
time, ultimately improving data quality with each merger.  To ensure transparency, the content of each 22 
merger together with cohort’s QA check feedback is summarized in a report. DMs extract data for 23 
projects based on specified and agreed eligibility criteria. After signing a data protection agreement, 24 
project leads are sent data extractions in a secure format. What has been found?  25 
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Projects within the COHERE collaboration have led to the publication of 28 articles in peer-reviewed 1 
journals as of April, 2016, contributing high-quality evidence that has informed clinical and public health 2 
decision-making.  3 
Prognosis and the effect of ART  4 
The “Prognosis and the effect of ART” group focuses on clinical outcomes in patients treated with cART. 5 
The effect of age on the response to cART was studied in around 50,000 antiretroviral-naive individuals. 6 
Older individuals were characterized by low pre-ART CD4 cell counts, and experienced poorer 7 
immunological responses but better virologic responses, indicating those who are diagnosed or treated 8 
late are at increased risk of clinical events.(8)  9 
Non-IDU HIV-infected individuals who achieved high CD4 cell counts after starting cART were found to 10 
have mortality patterns similar to those in the general population. Mortality was found to be persistently 11 
higher in individuals with a prior AIDS diagnosis (9), while the incidence of AIDS events continued to 12 
decline until CD4 cell counts were greater than 750 cells/mm3.(10) In patients with viral suppression, 13 
the risk of a new AIDS events or death followed a CD4 cell count gradient, even benefiting those with a 14 
CD4 cell count ≥500 cells/mm3.(11) Individuals who were virally suppressed on cART for more than three 15 
years but had incomplete CD4 cell recovery experienced substantially higher rates of mortality from 16 
both AIDS and non-AIDS causes, suggesting that these individuals should be monitored for diseases not 17 
conventionally considered HIV-related, especially non-AIDS defining cancers and liver diseases.(12) 18 
Future research will focus on new markers of the risk of morbidity and cause-specific mortality, 19 
outcomes in individuals treated for many years, and outcomes in people aging with HIV, particularly in 20 
the context of multi-morbidity and polypharmacy. 21 
The COHERE’s Pursuing Later Treatment Options (PLATO) II project looked at the rate of development 22 
of virologic failure in adults, adolescents and children. When virologic failure has occurred with at least 23 
two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), a non-nucleoside reverse 24 
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transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI), patients are said to have 1 
experienced triple class virologic failure (TCVF). Fewer than 9% of adult patients had experienced TCVF 2 
at year nine after starting cART.(13) The risk of TCVF was somewhat higher in children and particularly 3 
higher in adolescents.(14) Virologic suppression after TCVF was found to have increased from 20% in 4 
2000 to 58% in 2009. Rates of AIDS and death also declined over time in people with TCVF.(15) The 5 
incidence of TCVF in people on cART declined after 2008, and prevalence stabilized at around 2.5%.(16) 6 
An approximately linear inverse relationship between log10 viral load and CD4 cell count in people with 7 
TCVF points to likely immunologic benefits of reducing viral load, even by modest amounts, without 8 
necessarily resulting in an undetectable viral load.(17) 9 
Late Presentation 10 
Late presentation is defined as an HIV-diagnosis with a CD4 cell count <350/mm3 or an AIDS diagnosis, 11 
regardless of CD4 cell count, within six months of HIV-diagnosis. This definition was applied to 84,524 12 
PLWH presenting for care between January 1st, 2000 and June 30Th 2011 in Europe. Late presentation 13 
was present in over half (53.8%) of the sample. It decreased over time in both Central and Northern 14 
Europe among homosexual men and heterosexuals, but, in contrast, increased over time in Southern 15 
Europe among female heterosexuals and male IDUs and in Eastern Europe among IDUs. Late 16 
presentation was associated with increased mortality, especially in the first year after diagnosis, with 17 
significant variation across Europe.(18) Further analyses study changes in late presentation within 18 
different regions and demographic groups since 2010.(19) These findings have provided comprehensive 19 
evidence of patterns in late presentation in Europe and have informed discussions around earlier and 20 
more widespread testing for HIV and the importance of  linkage to HIV care.(20)    21 
Opportunistic Infections 22 
Thirty per cent of HIV infected people either present late with an OI or are at significant risk of an OI.(18) 23 
The COHERE OI group has described both the spectrum and incidence of OIs in patients on cART with 24 
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high CD4 cell counts.(10, 11) By including viral suppression as a cofactor, it was found that Pneumocystis 1 
jirovecii prophylaxis could safely be stopped in an additional 40% of patients when compared with 2 
guidelines based exclusively on CD4 cell counts,(21) findings which informed both the American and 3 
European treatment guidelines (22, 23). The group is conducting similar analyses for toxoplasmosis and 4 
other OIs and intends to reassess the guidelines on the timing for discontinuing secondary prophylaxes 5 
against specific OIs. 6 
While the early start of cART in the course of cryptococcal meningitis has been shown to be harmful in 7 
some clinical trials performed in resource-limited settings(24, 25), in Western settings with advanced 8 
clinical monitoring this may not be the case.(26) Current COHERE projects are examining the effect on 9 
mortality of the time of cART initiation after a diagnosis of cryptococcal meningitis or Toxoplasma gondii 10 
encephalitis. Preliminary results from a COHERE, NA-ACCORD and CNICS collaboration have shown that 11 
early cART did not increase mortality in AIDS patients with cryptococcal meningitis in high-income 12 
countries and overall mortality was lower than that reported by the clinical trials conducted in 13 
Africa.(27) Current analyses explore how specific OIs influence long-term immune reconstitution, 14 
morbidity and mortality in the most recent cART era.  15 
Malignancy 16 
The COHERE malignancy group has focused on defining the incidence, risk factors and prognosis of HIV-17 
associated cancers in the cART era, with a focus on systemic non-Hodgkin lymphoma (NHL) and primary 18 
brain lymphoma (PBL), Hodgkin’s lymphoma and, more recently, Kaposi’s sarcoma.(28-30) The 19 
incidence of non-Hodgkin’s lymphoma, primary brain lymphoma and Kaposi’s sarcoma were 20 
substantially reduced in patients on cART, and timely initiation of therapy at high CD4 cell counts is 21 
important for preventing these malignancies.(28, 30) In contrast, the incidence of Hodgkin’s lymphoma 22 
was not reduced by cART. Patients whose CD4 cell counts declined despite suppression of HIV-1 23 
replication on cART were at increased risk of Hodgkin’s lymphoma.(29) Comparative analyses are 24 
planned in collaboration with the African regions of IeDEA.(4) 25 
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Hepatitis  1 
The immunological changes over the course of HCV treatment and their effect on mortality were 2 
estimated in 6,433 HIV-HCV-co-infected adults (≥16), 12% of whom had initiated HCV treatment (n=692 3 
interferon and ribavirin; n=88 interferon alone). (31) CD4 cell counts decreased over the first 12 weeks, 4 
but stabilized from week 24 onwards with no negative impact on mortality. The group is poised to 5 
monitor the effect of the introduction of direct-acting antiviral agents in co-infected patients.  6 
Socio-economic inequalities  7 
The Socio-economic Inequalities group studies differences in key outcomes by sex, race/ethnicity, 8 
migrant status and educational level as a proxy for social class. Even in European countries with universal 9 
health care systems, it has been documented that individuals with lower educational level do not benefit 10 
equally from timely cART initiation and have a poorer response to cART.(32)  11 
Mortality in migrants has been found to be lower compared to native populations, which has been 12 
attributed to the “healthy migrant effect”. COHERE’s larger sample size has allowed this group to study 13 
mortality in men and women from multiple geographical origins separately, highlighting heterogeneity 14 
among migrant groups and revealing how certain groups are at an increased risk of mortality.(33) The 15 
group plans to examine differences in cause-specific mortality by country of origin.   16 
What are the main strengths and weaknesses?  17 
COHERE in EuroCoord’s infrastructure is a unique research platform which has prompted collaborations 18 
both within and beyond Europe. EuroCoord’s cross-network work packages on data capture, HIV 19 
tuberculosis, migrant health and modelling and its interdisciplinary working groups (clinicians, 20 
virologists, epidemiologists, biostatisticians) have formalized this cross network collaboration and 21 
fostered intra-European capacity building. COHERE’s further investment in data harmonization (HICDEP) 22 
has benefitted other regional collaborations. Efforts to streamline data submission with the CASCADE 23 
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and ART-CC cohort collaborations improved efficiency and reduced the workload of DMs. Finally, 1 
COHERE has provided excellent training opportunities for junior researchers (PhDs and Fellowships). 2 
COHERE’s greatest strength is its size, enabling stratification of subgroups of interest (8) (e.g. across 10 3 
age groups and sex-stratification) and the study of uncommon outcomes.(28)  The robustness of 4 
COHERE’s findings transcends Europe, benefiting the global HIV-patient community. COHERE data are 5 
highly representative of those in care in countries with large regional and national cohorts. Such cohorts 6 
enable COHERE to monitor trends across countries. However, adequate representation of marginalized 7 
groups such as migrant populations has become a challenge as a consequence of informed consent 8 
requirements in some countries as well as barriers to accessing care.(34)  9 
Although COHERE uses HICDEP, the heterogeneity in data quality remains an ongoing challenge. In 10 
collaboration with ART-CC (3), COHERE has been an ideal platform for harmonizing the collection and 11 
validation of causes of deaths in HIV-1 infected individuals. With a growing proportion of deaths now 12 
caused by non-AIDS events, accurately monitoring causes of death is critical to identify trends and 13 
evaluate risk factors. The progressive implementation of the “Coding Causes of Death in HIV” Protocol 14 
(CoDe), a uniform classification system for collecting and validating (via a centralized review process) 15 
data on causes of death and contributing factors in HIV-1 infected patients, developed by the D:A:D 16 
collaboration, has become a priority.(35)  17 
Despite COHERE’s demonstrated ability to evolve and adapt to respond to new research questions, it is 18 
now facing the challenge of expanding cohort and clinic-based databases to include clinical outcomes 19 
that were not initially of interest. As the cohort of PLWH in Europe ages, comorbidities, such as 20 
cardiovascular, metabolic, neurocognitive, and bone diseases, have become increasingly relevant to the 21 
study of prognosis in the era of cART. If COHERE and its contributing cohorts were formed today, more 22 
emphasis would be placed on linking HIV databases with other health databases (e.g. cancer registries, 23 
hospital or other administrative databases, etc.).  24 
14 
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COHERE from a patient’s perspective 1 
COHERE has maintained close ties with the patient community via its patient representative on the 2 
COHERE SC. Data from COHERE helped to demonstrate the value of high quality treatment strategies 3 
and enabled people living with HIV understand the evolving nature of the epidemic as well as face the 4 
ongoing challenges of growing older with HIV. Findings from COHERE have informed and guided the 5 
patient community’s discussions with governments and authorities about treatment guidelines and 6 
standards of care. 7 
Can I get hold of the data?  Where can I find out more? 8 
COHERE welcomes applications from Principal Investigators (PIs) of European cohorts interested in 9 
joining the COHERE collaboration. Interested cohorts must be willing to transform their data to fit 10 
HICDEP codes and adhere to the data submission timeline laid out in the COHERE Data Management 11 
SOP. COHERE DMs hold several explanatory webinars covering the data submission process to facilitate 12 
data transfer.  13 
Those interested in using COHERE data to conduct a project can download a COHERE Project Proposal 14 
Form and a Data Specification Form from our website (www.cohere.org). Proposals from external 15 
investigators will undergo the same rigorous scrutiny as those from investigators within the study group 16 
(details outlined in the COHERE Manual of Operations, available at www.cohere.org). 17 
Conclusion:  18 
COHERE is now a mature collaboration, which is unique in its size and coverage. It continues to produce 19 
new evidence on clinical outcomes, particularly AIDS-defining complications, late presentation and 20 
socio-economic inequalities, which inform clinical guidelines and public health policy recommendations. 21 
As PLWH live longer with a chronic infection, comparisons between them and cohorts of uninfected 22 
individuals are needed to disentangle the role of HIV infection from its long-term treatment and 23 
comorbidities, especially those linked to ageing.  24 
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Profile in a nutshell:  1 
 The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) is a project-driven 2 
cohort consortium that was set-up to address scientific questions that could not be addressed by single 3 
cohorts because of sample size requirements.  4 
 COHERE has grown from 33 cohorts in 2005 to 40 in 2015.  The 2014 merger, representing 14 projects, 5 
compiled data from 331 481 individuals from 34 European countries, including 2808 children (<13), 6 
representing 2 135 896 person-years of follow-up.  7 
 As a consortium of cohorts comprising clinic/hospital-based and interval cohorts, the frequency of patient 8 
follow-up varies. For clinic or hospital-based cohorts, average patient follow-up reflects current standards 9 
of care in those countries.  10 
 COHERE compiles data on clinical characteristics, antiretroviral therapy and other medications, estimated 11 
date of HIV seroconversion, opportunistic infections, laboratory results and socio demographic data 12 
according to the requirements of projects.  13 
 External collaborators interested in conducting a project in COHERE should submit a project proposal to 14 
the Regional Coordinating Centres in Bordeaux and Copenhagen for review by COHERE’s governing 15 
bodies (see www.cohere.org for further information). 16 
 17 
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